GSK-25

• Description :

  GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM) . GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM) . GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively) [1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Ribosomal S6 Kinase (RSK) ; ROCK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/gsk-25.html

• Concentration :

  10mM

• Purity :

  99.68

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  ClC1=CC(C2=NC(C3=C(F)C=C(Cl)C=C3)C(C(NC4=C(F)C=C(NN=C5)C5=C4)=O)=C(C)N2)=CC=N1

• Molecular Formula :

  C24H16Cl2F2N6O

• Molecular Weight :

  513.33

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Sehon CA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008 Nov 13;51 (21) :6631-4.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [874119-56-9]